Dec 26 (Reuters) - Johnson & Johnson said on Friday it has discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis, after it failed to meet efficacy goals in an interim analysis.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar)
